3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
28
Unknown
9
Terminated
7
Recruiting
7
Withdrawn
5
Active not recruiting
2
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
88
Head & Neck
55
Gastrointestinal
39
Genitourinary
28
Gynecologic
24
Breast
11
CNS
10
Other solid neoplasm
8
Dermatologic
7
Lymphoid
6
Plasma cell
5
Endocrine
3
Tumor-Agnostic
2
Sarcoma
2
Myeloid
1
Conditions
Neoplasms, Second Primary
1
Neoplasm Metastasis
1
Carcinoma
1
Interventions
pembrolizumab
17
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Bevacizumab
8
Paclitaxel
7
Biopsy
7
Nivolumab
6
atezolizumab
5
Surveys and Questionnaires
4
Standard of Care
4
Radiosurgery
4
Practice Guidelines as Topic
4
Pemetrexed
4
Oxaliplatin
4
Cyclophosphamide
4
Carboplatin
4
osimertinib
3
niraparib
3
durvalumab
3
cemiplimab
3
avelumab
3
Radiotherapy
3
Radiation
3
Leucovorin
3
Irinotecan
3
Ipilimumab
3
Interviews as Topic
3
Fluorouracil
3
trastuzumab deruxtecan
2
trametinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Cisplatin
×
Tumor-Agnostic
×
Clear all
NCT05261399
2026-04-06
SAFFRON
AstraZeneca
Phase 3
Active not recruiting
345 enrolled
NCT03199300
2025-12-11
InvestiCAT
University Medical Center Groningen
Active not recruiting
20 enrolled